To characterize the molecular mechanisms involved in the carcinogenesis and progression of small-cell lung cancer (SCLC) and identify molecules to be applied as novel diagnostic markers and/or for development of moleculartargeted drugs, we applied cDNA microarray profile analysis coupled with purification of cancer cells by laser-microbeam microdissection (LMM). Expression profiles of 32,256 genes in 15 SCLCs identified 252 genes that were commonly upregulated and 851 transcripts that were down-regulated in SCLC cells compared with non-cancerous lung tissue cells. An unsupervised clustering algorithm applied to the expression data easily distinguished SCLC from the other major histological type of non-small cell lung cancer (NSCLC) and identified 475 genes that may represent distinct molecular features of each of the two histological types. In particular, SCLC was characterized by altered expression of genes related to neuroendocrine cell differentiation and/or growth such as ASCL1, NRCAM, and INSM1. We also identified 68 genes that were abundantly expressed both in advanced SCLCs and advanced adenocarcinomas (ADCs), both of which had been obtained from patients with extensive chemotherapy treatment. Some of them are known to be transcription factors and/or gene expression regulators such as TAF5L, TFCP2L4, PHF20, LMO4, TCF20, RFX2, and DKFZp547I048 as well as those encoding nucleotide-binding proteins such as C9orf76, EHD3, and GIMAP4. Our data provide valuable information for better understanding of lung carcinogenesis and chemoresistance.
Introduction
A number of genetic alterations associated with development and progression of lung cancer, one of the tumors showing the worst prognosis, have been reported, but its precise molecular mechanisms remain unclear (1) . Two major histologicallydistinct types of lung cancer, non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) have different pathophysiological and clinical features that suggest differences in the mechanisms of their carcinogenesis. SCLC accounts for 15-20% of all lung cancers (2, 3) and is categorized as neuroendocrine tumors of the lung with certain morphologic, ultrastructural, and immunohistochemical characteristics. Some paraneoplastic syndromes such as inappropriate secretion of antidiuretic hormone, ectopic Cushing's syndrome, and the Lambert-Eaton myasthenic syndrome (LEMS) are known to be associated with SCLC, however, the detailed molecular characteristics of neuroendocrine tumors are still not well understood. Although patients with SCLC respond favorably to 1st line multi-agent chemotherapy, they often relapse in a short time. Hence, only 20% of patients with limited-stage disease (LD) can be cured with combined modality therapy and <5% of those with extensive-disease (ED) can achieve 5-year survival after the initial diagnosis (4, 5) . Therefore, new therapeutic strategies such as molecular-targeted agents are eagerly awaited.
The genome-wide cDNA microarray analysis enabled us to obtain comprehensive gene expression profiles related to detailed phenotypic and biological information in cancer cells (6) (7) (8) . This approach is also useful to identify unknown molecules involved in the pathways of lung carcinogenesis (9) (10) (11) . We, in fact, have identified multiple applicable targets for development of novel anti-cancer drugs and/or diagnostic markers (12) (13) (14) (15) (16) (17) .
Through gene-expression profile analysis of 15 SCLCs coupled with purification of cancer cell population by lasermicrobeam microdissection (LMM) on a cDNA microarray consisting of 32,256 cDNAs, we identified a number of genes that were expressed differently between the two most common histological types of lung cancer, NSCLC and SCLC. We report important information regarding the mechanisms of lung carcinogenesis and chemoresistance as well as the discovery of potential targets for development of diagnostic markers and signal-suppressing therapeutic strategies for lung cancer treatment.
Materials and methods
Patients and tissue samples. Advanced SCLC tissue samples were obtained with informed consent from post-mortem materials (15 individuals) at Hiroshima University (Hiroshima, Japan). Individual institutional ethical committees approved the use of all clinical materials. Patients' clinical information was obtained from medical records. All samples were immediately frozen and embedded in TissueTek OCT medium (Sakura, Tokyo, Japan) and stored at -80˚C until use for microarray analysis.
Laser-microbeam microdissection, extraction of RNA and T7-based RNA amplification. Cancer cells were selectively collected from the preserved samples using laser-microbeam microdissection (10, 11) . The quality of RNAs extracted from the residual tissue of each case was checked by electrophoresis in the degenerative agarose gel and ensured by a presence of clear ribosomal RNA bands. Extraction of total RNA and T7-based amplification were performed as described previously (10, 11) . As a control probe, normal human lung poly(A) RNA (BD Biosciences Clontech, Palo Alto, CA) was amplified in the same manner; 2.5 μg each of amplified RNAs (aRNAs) from each cancerous tissue and that from the control were reversely transcribed in the presence of Cy5-dCTP and Cy3-dCTP, respectively. cDNA microarrays. Our genome-wide cDNA microarray system containing 32,256 cDNAs that were selected on the basis of the information in the UniGene database (build #188) of the National Center for Biotechnology Information (NCBI) was used for this analysis. Fabrication of the microarray, hybridization, washing, and detection of signal intensities were described previously (10, 18) .
Data analysis. Signal intensities of Cy3 and Cy5 from the 32,256 spots were quantified and analyzed by substituting backgrounds, using ArrayVision software (Imaging Research Inc., Ontario, Canada). Subsequently, the fluorescent intensities of Cy5 (tumor) and Cy3 (control) for each target spot were adjusted so that the mean Cy5/Cy3 ratio of 52 housekeeping genes on the array was equal to one. Because data derived from low signal intensities are less reliable, we determined a cut-off value on each slide as described previously (10) and excluded genes from further analysis when both Cy3 and Cy5 dyes yielded signal intensities lower than the cut-off. For other genes, we calculated the Cy5/Cy3 ratio using the raw data of each sample.
Cluster analysis of SCLC and NSCLCs. We applied a hierarchical clustering method to both genes and tumors. To obtain reproducible clusters for classification of the 15 SCLC, and an independent set of 62 NSCLC (20 early-stage ADC, 15 early-stage SCC, and 27 advanced ADC) samples analyzed previously using a cDNA microarray containing a subset (27,648 genes) of 32,256 genes on our present microarraysystem (data from refs. 9 and 11, and our unpublished data for the expression of 4608 genes in the same set of 35 earlystage NSCLC), we selected genes from them for which valid data were obtained in 80% of the experiments, and whose expression ratios varied by standard deviations of >1.7. The analysis was performed using web-available software ('Cluster' and 'TreeView') written by M. Eisen (http://rana. lbl.gov/ index.htm). Before applying the clustering algorithm, we log-transformed the fluorescence ratio for each spot and then median-centered the data for each sample to remove experimental biases.
Semi-quantitative RT-PCR. We selected highly up-regulated genes and examined their expression levels by means of semiquantitative RT-PCR experiments as previously described (16) . aRNA (3 μg) from each sample was reversely transcribed to single-stranded cDNAs using random primer (Roche) and Superscript II (Invitrogen). Semi-quantitative RT-PCR experiments were carried out with the following sets of synthesized primers specific to the 10 representative genes that were up-regulated in SCLCs or with ß-actin (ACTB)-specific primers as an internal control: K562 cell-derived leucine-zipper-like protein 1 (KLP1), Immunohistochemical analysis. To confirm the differential protein expression of 2 candidate markers (SCAMP5 and CDC20), which were highly up-regulated in SCLC, we stained clinical tissue sections using ENVISION + Kit/HRP (DakoCytomation). Briefly, after endogenous peroxidase and protein blocking reactions, anti-human SCAMP5 polyclonal antibody (Medical & Biological Laboratories, Aichi, Japan) or anti-human CDC20 monoclonal antibody (Santa Cruz Biotechnology, CA) was added, and then HRP-labeled anti-rabbit or anti-mouse IgG as the secondary antibody. Substrate-chromogen was then added and the specimens were counterstained with hematoxylin.
Results

Identification of genes commonly up-and down-regulated in SCLCs.
To obtain precise gene expression profiles of SCLC cells, we collected pure populations of cancer cells by LMM to minimize contamination of the tumor cells by non-cancerous cells (Fig. 1) . We identified up-and down-regulated genes common to SCLC according to the following criteria: i) genes for which we were able to obtain expression data in >80% (at least twelve of the 15 cases) of the cases examined; and ii) genes whose expression ratio was >10.0 or <0.1 in at least 50% of the informative cases. According to these criteria, a total of 252 genes were listed up as commonly up-regulated and 851 genes as commonly down-regulated in SCLC (representative genes are listed in Table I ). The up-regulated genes represented a variety of functions including genes associated with cell adhesion and cytoskeleton, signal transduction, cell proliferation, and some kinases ( Table I) . Some of the transactivated genes included in the list, such as GRP, SKP2 and INSM1 were previously reported by others (19) (20) (21) .
Validation of selected genes by semi-quantitative RT-PCR and immunohistochemical analyses.
To validate the expression data obtained by microarray analysis, we performed semiquantitative RT-PCR experiments for 10 representative genes, which were indicated to be overexpressed commonly in SCLCs ( Fig. 2A) . The results of RT-PCR experiments were quite concordant with those of the microarray data. To further validate the data at the protein level, we carried out immunohistochemical analysis using the paired tumor and normal tissue sections using antibodies for SCAMP5 or CDC20 (Fig. 2B) . Both proteins were confirmed to be expressed abundantly in SCLCs, but were hardly detectable in normal lung.
Cluster analysis of gene expression in lung cancers. We then applied an unsupervised two-dimensional hierarchical clustering algorithm to analyze similarities among samples and among genes, using data obtained from expression profiles of 15 advanced SCLCs as well as 35 early-stage NSCLCs (ADC and SCC) and 27 advanced NSCLCs (ADC) which we previously analyzed and reported (9,11) (Fig. 3A) . Since the 62 NSCLC samples had been analyzed for a subset (27,648 genes) of the 32,256 genes on our present microarray-system, we analyzed the information of a subset of the 27,648 genes for which valid values could be obtained in >80% of the cases examined. We also excluded genes with observed standard deviations of <1.7. The 475 genes that passed through this cut-off filter were analyzed further.
In the sample axis (horizontal) in Fig. 3A , 81 samples (four cases were examined in duplicate to validate the reproducibility and reliability of our experimental procedure), 77 cases were clustered into two major groups on the basis of their expression profiles. The dendrogram shown at the top of Fig. 3 represents similarities in expression patterns among individual cases; the shorter the branches are, the greater the similarities are. The four duplicated cases (no. 13, 20, K91, and LC12) that were labelled and hybridized in independent experiments were clustered most closely within the same group (Fig. 3B) . The identical genes spotted on different positions on the slide glasses were also clustered into adjacent rows (Fig. 3B) . These results supported the high reproducibility and reliability of our experimental procedures. Of the 77 cases, 15 SCLC clustered into one major group and 20 early-stage ADC and 15 SCC as well as 27 advanced ADC clustered into individual groups.
Clearly, SCLC and NSCLC appeared to have different gene expression profiles that could reflect differences in the etiological and clinicopathological natures.
In this analysis, we obtained 34 genes which were expressed abundantly in SCLC, some of which revealed characteristics of certain neuronal functions such as neurogenesis and neuroprotection (Cluster-1 in Fig. 3A and B; Table IIA; i.e.
DPYSL2, ADNP etc).
Identification of genes related to chemoresistance. Since chemoresistance is a major obstacle for cancer treatment, identification of genes commonly up-regulated in cancer cells obtained from patients who had failed certain chemotherapy is an effective approach to understand the mechanism of chemoresistance and develop a novel cancer therapy that overcomes this problem. We obtained 68 genes expressed abundantly both in advanced SCLCs and advanced ADCs (Cluster-2 in Fig. 3A and C; Table IIB), both of which were obtained from patients who had extensive chemotherapy treatments (although the chemotherapy protocols provided to these patients were not the same). Some of them are known to be transcription factors and/or gene expression regulators such as TAF5L, TFCP2L4, PHF20, LMO4, TCF20, RFX2, Table I . Representative up-regulated genes in SCLC with known function. Figure 3 . Dendrogram of two-dimensional hierarchical clustering analysis of genes across samples from 77 lung cancer cases. Red and green indicate transcript levels respectively above and below the median for the respective gene across all samples. Black, unchanged expression; gray, no detectable expression. In the horizontal axis representing 77 lung cancers, 15 advanced SCLCs, 35 early-stage NSCLCs (20 ADCs and 15 SCCs) and 27 advanced ADCs were separated in four trunks. In the vertical axis the 475 genes were clustered in different branches according to similarities in relative expression ratio (A). Cluster-1 includes genes which expressed more abundantly in SCLCs than in NSCLCs. The four duplicated cases (no. 13, 20, K91, and LC12) that were labelled and hybridized in independent experiments were clustered most closely within the same group. Identical genes spotted on different positions on the slide glasses were also clustered into adjacent rows (orange square) (B). Cluster-2 includes genes which commonly expressed in advanced SCLCs and NSCLCs, both of which had been treated with chemotherapy (C). Table II . A, list of 34 genes expressed abundantly in SCLCs.
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and DKFZp547I048. Furthermore, some genes encoding nucleotide-binding proteins such as C9orf76, EHD3, and GIMAP4 were also found in the list.
Discussion
Chemotherapy remains as the essential component for treatment of patients with SCLC, regardless of their stage (either LD or ED) or performance status. In LD, a combination of chemotherapy with radiation therapy improves patient prognosis better than chemotherapy alone (22, 23) . SCLC is usually sensitive to chemotherapy and radiotherapy in first-line treatment, but the period of good response is often very limited and most of the patients ultimately relapse with treatment-resistant disease. Hence, the final outcome of SCLC patients is poor with an overall 5-year survival rate of <10%. Therefore, it is urgently required to develop novel diagnostic tools for detection of cancer at a much earlier stage and to develop molecular-targeted therapies such as small-molecular compound and immunotherapies targeting cancer-specific molecules. Gene expression profile of SCLC is the first step to identify the appropriate candidate molecules for such purposes. To analyze the gene expression profile of SCLC, we used genome-wide cDNA microarray consisting of 32,256 cDNA clones in combination with laser-microdissection technology to represent the expression profile of a highly pure population of SCLC cells. To our knowledge, this is the first report of comprehensive gene expression profiles of pure SCLC cells derived from laser-microdissected clinical tissue samples. Through the detailed genome-wide expression data of 32,256 genes, we identified 252 transcripts that were commonly up-regulated in SCLCs. These genes encode proteins with a variety of functions that include transmembrane/secretory proteins, and cancer-testis or onco-fetal antigens as well as proteins important in cell adhesion, cytoskeleton structure, signal transduction, and cell proliferation. Some of them should be useful as diagnostic/prognostic markers and probably as therapeutic targets for development of new molecular-targeted agents or immunotherapy for lung-cancer treatment. Tumorspecific transmembrane/secretory proteins should have significant advantages, because they are presented on the cell surface, making them easily accessible as molecular markers and therapeutic targets. Some tumor-specific markers available at present, such as CYFRA or Pro-GRP, are transmembrane/ secretory proteins (19, 24) . An example of rituximab (Rituxan), a chimeric monoclonal antibody against CD20-positive lymphomas, provides proof of the concept that targeting specific cell-surface proteins can provide significant clinical benefits (25) . On the other hand, among tumor antigens identified to date, cancer-testis antigens (CTAs) have been recognized as a group of highly attractive targets for cancer vaccine. Although other factors, such as the in vivo immunogenicity of the protein are also important and further examination will be necessary, our candidate genes include known CTA such as TSGA14. Further study using this expression profile will doubtlessly enable us to identify novel CTAs that could be a good target for immunotherapy of SCLC.
Chemoresistance is clinically a very important issue that we need to overcome for an improvement in the treatment of patients with advanced or end-stage cancer. Our gene expression profile data obtained from the fifteen autopsy samples as well as advanced ADCs with the clinical history of chemotherapy (Cluster-2 in Fig. 3A and C; Table IIB) were considered to reflect the characteristics of advanced lung cancers with acquired chemoresistance. Unsupervised cluster analysis of these subgroups identified up-regulated genes including TAF5L, TFCP2L4, PHF20, LMO4, TCF20, and RFX2 that were known to have transcription factor activities. Some transcription factors were reported to be associated with acquired chemoresistance. For example, constitutive activation of NF-κB, a transcription factor involved in multiple cellular processes, appears to support cancer cell survival and to reduce the sensitivity against chemotherapeutic drugs (26) . On the other hand, some genes in the list, i.e. C9orf76, EHD3, and GIMAP4, were found to bind to the nucleotide. Since some DNA-binding proteins were known to play a critical role in the DNA-repair process, the genes shown above might also have some functions in DNA repair and contribute to increase in chemoresistance. Further analysis of the genes in this group might be important for the development of novel therapies for chemoresistant tumors.
Neuroendocrine tumors of the lung range from welldifferentiated neuroendocrine carcinoma (typical carcinoid) to intermediate grade (atypical carcinoma) or to very aggressive poorly differentiated lesions (large cell neuroendocrine carcinoma (LCNEC) and SCLC). SCLC is generally considered as a major neuroendocrine tumor of the lung, and causes several paraneoplastic neuroendocrine syndromes. These syndromes represent clinically distinct symptoms in SCLC patients. Up-regulated genes included several genes which were related to the neuroendocrine function such as insulinoma-associated 1 (INSM1), chromogranin A (parathyroid secretory protein 1; CHGA), and achaete-scute complex-like 1 (Drosophila; ASCL1), further supporting the strong relationship between SCLC and neuroendocrine syndromes at molecular levels. Our gene list might also include a set of genes related to some cancer-related syndromes including cachexia.
In conclusion, our cDNA microarray analysis combined with an LMM system revealed most comprehensive gene expression profiles of SCLC involving up-regulated genes that encode proteins with the function of cell cycle/growth, and signal transduction, or products with unknown function as well as transmembrane/secretory proteins and CTAs. The information could offer a powerful strategy for rapid identification and further evaluation of target molecules for a personalized therapy.
